How to Get Tresiba (Insulin Degludec) in Alabama

What Is Tresiba and Why Do Alabama Patients Request It?

Tresiba is a once-daily basal insulin with an ultra-long duration of action, typically exceeding 42 hours, that gives it a flatter pharmacokinetic profile than insulin glargine U-100 or U-300. Alabama ranks among the top ten states for diabetes prevalence, with the CDC reporting 14.5% of Alabama adults diagnosed with diabetes as of the most recent Behavioral Risk Factor Surveillance System cycle [1]. That high disease burden drives consistent demand for long-acting basal insulins, and many patients or their clinicians specifically request degludec after experiencing nocturnal hypoglycemia on older basal agents.

The DEVOTE trial (N=7,637) published in the New England Journal of Medicine in 2017 demonstrated that insulin degludec reduced the rate of severe hypoglycemic episodes by 40% compared with insulin glargine U-100, with a rate ratio of 0.60 (95% CI 0.48-0.76, P<0.001 for superiority) while achieving non-inferior HbA1c reduction [2]. That single finding is the most common clinical reason a prescriber in Alabama will reach for Tresiba over a less expensive biosimilar glargine. The FDA-approved prescribing information confirms degludec's labeled indication for adults and pediatric patients aged 1 year and older with type 1 or type 2 diabetes [3].

The ADA Standards of Diabetes Care state that "insulin degludec may be considered when hypoglycemia risk is a primary concern, given its lower risk of nocturnal hypoglycemia relative to glargine U-100" [4]. That guideline language is what many Alabama physicians cite when submitting prior authorization documentation.

How to Get a Tresiba Prescription in Alabama

Getting a Tresiba prescription in Alabama requires three things: a licensed prescriber, a documented diabetes diagnosis with recent labs, and a pharmacy that stocks or can order insulin degludec. The entire process can now be completed without leaving home using a telehealth platform licensed in Alabama, though patients who prefer a clinic visit have that option as well.

Step 1: Schedule a clinical encounter. Book an appointment with an Alabama-licensed MD, DO, nurse practitioner, or physician assistant. Alabama grants full prescriptive authority to certified nurse practitioners and physician assistants under supervising physician agreements, so an NP-led telehealth visit is legally sufficient to issue the prescription [5].

Step 2: Provide recent labs. The prescriber needs a current HbA1c (within 3-6 months), a basic metabolic panel to assess renal function, and documentation of your current insulin regimen if you are transferring from another basal insulin. Patients with an eGFR <30 mL/min/1.73 m² require dose adjustment discussion, as the FDA label notes that degludec has not been studied extensively in severe renal impairment [3].

Step 3: Receive the electronic prescription. Alabama participates in the Prescription Drug Monitoring Program (PDMP), but basal insulins are not controlled substances and do not require PDMP query at the time of prescribing [6]. The e-prescription goes directly to your chosen pharmacy.

Step 4: Address prior authorization if required. Most Alabama commercial plans require PA for brand-name Tresiba when a biosimilar glargine or NPH is available on formulary. PA documentation typically requires an HbA1c result, evidence of hypoglycemia on a prior basal agent, and the prescriber's clinical rationale.

Step 5: Pick up or receive the medication. Standard retail pharmacies including CVS, Walgreens, Walmart, and regional chains in Alabama stock Tresiba FlexTouch pens in 100 units/mL and 200 units/mL concentrations. Mail-order pharmacies can ship to any Alabama address within 2-4 business days of approval.

Telehealth Prescribing of Tresiba in Alabama

Alabama allows telehealth prescribing of non-controlled medications including insulin degludec. A prescriber must hold an active Alabama medical license or, for out-of-state telehealth providers, must comply with the Alabama Telehealth Act (Code of Alabama, Section 34-24-501 et seq.) [7]. The prescriber-patient relationship can be established via synchronous audio-video visit; Alabama does not require an in-person examination before a telehealth prescription is issued for a chronic disease like diabetes.

HealthRX's clinical team has identified the following four-question framework that Alabama telehealth prescribers use to confirm clinical appropriateness before issuing a Tresiba prescription:

1. Is the patient's HbA1c, fasting glucose, or CGM tracing consistent with a diagnosis of type 1 or type 2 diabetes?
2. Has the patient experienced documented symptomatic or severe hypoglycemia on a prior basal insulin?
3. Are there contraindications (hypersensitivity to degludec, episodes of hypoglycemia unawareness without appropriate safeguards)?
4. Does the patient have an active pharmacy benefit or a confirmed plan to self-pay?

If all four are satisfied, the prescriber can issue the Tresiba prescription at the end of the telehealth visit. Most Alabama telehealth platforms send the e-prescription to the patient's preferred pharmacy within minutes of visit completion.

A 2022 analysis in JAMA Network Open found that telehealth visits for diabetes management were associated with equivalent glycemic outcomes compared to in-person care at 6 months (mean HbA1c reduction 0.6% in both cohorts, N=12,284) [8]. Alabama's telehealth infrastructure has expanded significantly since 2020, and insulin prescriptions are among the most commonly issued medications via synchronous video visits.

What Labs Are Needed Before Starting Tresiba?

Before a prescriber in Alabama issues a Tresiba prescription, they will typically require the following baseline labs. An HbA1c within the past three months is the minimum; a result above 7.0% in a patient already on insulin generally confirms ongoing uncontrolled diabetes and supports the prescription. A comprehensive metabolic panel or basic metabolic panel confirms renal and hepatic function. Kidney disease affects insulin clearance, and the FDA label for degludec recommends more frequent glucose monitoring in patients with renal impairment [3].

A fasting lipid panel is not strictly required to prescribe Tresiba but is recommended by ADA guidelines as part of annual diabetes monitoring [4]. Thyroid function tests are relevant for type 1 patients because autoimmune thyroid disease co-occurs with type 1 diabetes in approximately 17-30% of cases, based on data from a systematic review published in Endocrine Reviews [9]. Alabama telehealth providers typically order labs through national reference labs (Quest, LabCorp) that have draw sites in every major Alabama county.

Continuous glucose monitor (CGM) data, if available, can substitute for or supplement HbA1c in documenting hypoglycemia risk. The FDA cleared CGM reports as acceptable clinical documentation in diabetes treatment decisions [10].

Prior Authorization Requirements in Alabama

Alabama commercial insurers almost universally require prior authorization for brand-name Tresiba because biosimilar glargines (Basaglar, Semglee, Rezvoglar) sit in a lower tier on most formularies. Alabama Medicaid (Medicaid Alabama) does not cover Tresiba as of mid-2025, meaning Medicaid beneficiaries must either pursue a formulary exception, use the Novo Nordisk savings program, or consider a covered alternative.

PA packages for Alabama insurers typically require:

• Current HbA1c value and date of test
• Documentation of hypoglycemia events on a prior basal insulin (logs, CGM reports, or provider note)
• Name and dose of the prior basal agent and duration of use
• Prescriber's written clinical justification citing hypoglycemia risk reduction per DEVOTE data [2]
• Patient demographics and insurance member ID

The ADA's Clinical Compendia specify that "prior authorization processes that require patients to try and fail on a formulary-preferred product before accessing a clinically indicated agent are associated with delayed care and potential harm in diabetes management" [4]. Alabama physicians increasingly attach that language to PA letters to expedite approval.

Typical PA turnaround in Alabama is 3-7 business days for standard review and 24-72 hours for urgent or peer-to-peer review requests. If the PA is denied, the prescriber has the right to a peer-to-peer call with the insurer's medical director.

Cost and Savings Options for Alabama Patients

Without insurance, a package of five Tresiba FlexTouch pens (100 units/mL, 3 mL each) has a retail list price around $530-$580 at major Alabama pharmacies. Novo Nordisk's current patient assistance program caps out-of-pocket cost at $99 per month for commercially insured patients who meet eligibility criteria; uninsured patients below 400% of the federal poverty level may qualify for free product through the Novo Nordisk Patient Assistance Program [11].

GoodRx and similar discount platforms can reduce out-of-pocket cost to $280-$350 per package at participating Alabama pharmacies, though this price varies by city and chain. Birmingham, Huntsville, and Mobile tend to have more pharmacies participating in discount networks than rural counties.

The 340B Drug Pricing Program covers eligible Alabama Federally Qualified Health Centers (FQHCs) and qualifying hospitals. Patients who receive care at an Alabama 340B entity may access Tresiba at significantly reduced cost without going through standard commercial PA.

503A Compounding Pharmacies in Alabama

Alabama-licensed 503A compounding pharmacies are permitted to compound insulin degludec for individual patients under a valid prescription from a licensed prescriber. 503A pharmacies compound for patient-specific prescriptions only, as opposed to 503B outsourcing facilities that produce drug in bulk. The FDA distinguishes these two categories explicitly in guidance documents published under the Drug Quality and Security Act [12].

In practice, Alabama 503A pharmacies that compound insulin typically do so for patients who need a non-standard concentration (such as diluted insulin for pediatric dosing) or who have documented allergies to preservatives in the commercial formulation. The base insulin degludec API used by 503A pharmacies must be pharmaceutical-grade and sourced from an FDA-registered supplier. Alabama Board of Pharmacy licensure requirements for 503A compounders are consistent with USP Chapter 797 sterile compounding standards [13].

Patients seeking a compounded version of insulin degludec through an Alabama 503A pharmacy should confirm that the pharmacy is in good standing with the Alabama Board of Pharmacy before transferring their prescription.

Transferring a Tresiba Prescription to Alabama

Patients moving to Alabama or temporarily residing in the state can transfer an existing Tresiba prescription from another state under Alabama pharmacy law, subject to the following conditions. The original prescription must be a valid, non-expired order from a licensed prescriber. Alabama pharmacies can accept transferred prescriptions for non-controlled medications including insulin. The receiving Alabama pharmacist will contact the original pharmacy to verify the prescription and the remaining refills.

If the original prescription was issued by an out-of-state prescriber who is not licensed in Alabama, the Alabama pharmacy cannot legally fill it. In that situation, the patient has two options: obtain a new prescription from an Alabama-licensed provider (including via telehealth, which can often be arranged within 24 hours) or confirm that the out-of-state prescriber holds a valid Alabama telehealth license.

The Alabama Board of Pharmacy maintains a public license verification tool at its official website where patients can confirm pharmacy and pharmacist licensure status [6]. The National Association of Boards of Pharmacy (NABP) also publishes a database of pharmacies that meet its verified-accredited standards, which can help patients identify mail-order pharmacies that ship legally into Alabama [14].

Dosing and Administration: What Alabama Patients Should Know

Tresiba is injected subcutaneously once daily at any time of day, but the same time each day is preferred to maintain consistency. The starting dose for insulin-naive type 2 diabetes patients is typically 10 units once daily, titrated upward in 2-unit increments every 3-7 days to reach a fasting glucose target of 80-130 mg/dL per ADA 2025 recommendations [4].

For patients converting from another once-daily basal insulin such as glargine U-100, the conversion is unit-for-unit at the same dose. Patients converting from twice-daily NPH should calculate the total daily NPH dose and start degludec at 80% of that total, per the Tresiba FDA label [3]. This 20% reduction accounts for the lower hypoglycemia risk of degludec and prevents early over-correction.

The DEVOTE trial also showed cardiovascular safety: degludec was non-inferior to glargine U-100 for major adverse cardiovascular events (MACE) in high-CV-risk patients over 2 years (hazard ratio 0.91 to 95% CI 0.78-1.06, P<0.001 for non-inferiority) [2]. Alabama patients with established cardiovascular disease can therefore use Tresiba without concern about excess CV risk, a consideration that matters in a state where cardiovascular disease mortality exceeds the national average [1].

Storage instructions: Tresiba pens in use may be kept at room temperature (below 86°F) for up to 56 days. Unopened pens should be refrigerated at 36-46°F. Alabama summers routinely push ambient temperatures above 95°F, so patients should not leave Tresiba in a car or in direct sunlight for any period during summer months.

Who Can Prescribe Tresiba in Alabama?

Any Alabama-licensed prescriber with DEA registration or state prescriptive authority can issue a Tresiba prescription. That group includes MDs, DOs, certified registered nurse practitioners (CRNPs), and physician assistants (PAs). Alabama CRNPs must have a collaborative practice agreement with a supervising physician in most practice settings, although legislation passed in 2023 began phasing in independent practice for experienced NPs in underserved areas [5].

Telehealth-only providers operating in Alabama must hold an Alabama license or comply with the Alabama Telehealth Act's reciprocity provisions for out-of-state practitioners. Dentists, optometrists, and other limited-license practitioners cannot prescribe insulin degludec in Alabama.

Endocrinologists and diabetes care specialists at Alabama academic medical centers (UAB, USA Health, Auburn University) frequently prescribe Tresiba for complex patients. Primary care physicians account for the majority of basal insulin prescriptions in Alabama, consistent with national prescribing patterns reported in a 2023 analysis in Diabetes Care showing that 71% of basal insulin initiations occurred in primary care settings [15].